In Brief: Possis Medical
This article was originally published in The Gray Sheet
Executive SummaryPossis Medical: Submits revised 510(k) to FDA for use of its AngioJet Rapid Thrombectomy System in peripheral vessels. The submission was made in response to questions raised by FDA on an initial 510(k) submitted in March ("The Gray Sheet" June 24, In Brief)...
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.